Private Equity

After several years of slowing deal activity, bankers and private equity firms are again eyeing physician practices for deals in 2025. 

Healthcare private equity firms have been at the center of controversy in recent months after a year of notable Chapter 11 filings and increased regulatory scrutiny from a number of states. 

At least six state legislatures have introduced bills in the last two weeks to increase regulatory scrutiny of private equity mergers and acquisitions in the healthcare space. 

While private equity activity in healthcare has been high over the last several years, a more recent rise in bankruptcies and defaults points to a possible rough patch for healthcare PE investments. 

Here are what three ASC leaders outlined as pros and cons of private equity in the ASC industry:

On Jan. 8, Gov. Maura Healey signed a bill into law that will increase scrutiny of healthcare transactions, according to a Jan. 10 report from The National Law Review.

Massachusetts Gov. Maura Healey is again eyeing legislation that would increase oversight of private equity activity in healthcare, Mass Live reported Jan. 2. 

While many ASCs remain independent, private equity has become an established force in the industry, with notable movements in 2024.

California and Massachusetts both attempted to pass legislation that would tighten regulations around private equity transactions in healthcare, but it is unlikely that either state will see the proposed bills become law before the end of 2024, Bloomberg reported Dec.…

Here are five recent private equity deals, finalized or rumored, that ASCs are eyeing: